CT SB01473

Commissioner of Social Services must provide Medicaid coverage for FDA-approved gene therapies to treat sickle cell disease, effective upon passage

Commissioner required to apply for federal initiatives to increase cost-effective access, including the Cell and Gene Therapy Access Model administered by CMS

Report due to the General Assembly's human services committee by January 1, 2026

Report must include: efforts to increase cost-effective access, number of Medicaid recipients receiving coverage, cost to the state, and estimated appropriations needed for continued coverage